Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Eligibility issues, a need for better multidisciplinary collaboration, and a lack of incorporation in community practices are ...

Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

J. Scott Cordova, M.D., Ph.D., has joined the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller ...

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

Cancer patients face more than just the disease. They spend countless hours commuting, waiting, and undergoing treatment.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.